News

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has filed an ANDA with the FDA seeking approval to market Mesalamine delayed-release tablets, 1.2g, a generic version of Shire’s Lialda.

The funds will be used to support R&D and clinical studies on the company’s oral insulin capsule and oral GLP-1 analog from December 2011 to November 2012. Oramed

According to the agreement, Desitin will be licensee for MT 400 in the licensed territory and will be in charge of the remaining clinical development, manufacturing and commercialization.

The supplements include Fit Eye, Fit Joint, Fit Bone, Fit Heart, Fit Artery, Fit Menopause and Fit Prostate. Fit Eye offers bioactives derived from the potent sources, including

The funding aims to advance the development of antiviral therapeutics for treating diseases caused by Ebola, plague, Japanese encephalitis, and other lethal pathogens. UW researchers will provide bioinformatics

The initiative will help increase the supply of Optison, meeting the current market demand. Optison is a sterile non-pyrogenic suspension of microspheres of human serum albumin with perflutren

The trial which will be conducted at approximately 40 sites worldwide, including the US, Western Europe, and Asia, is expected to enroll 260 patients. The overall survival is

The companies kept the terms of the agreement confidential. Marina Biotech president and chief executive officer Michael French said, "We view this license as yet another important validation

The generic version of Pfizer’s Lipitor is indicated for the treatment of hypercholesterolaemia and to prevent cardiovascular disease. The company is launching the product in Teva 360 livery,